$5.59 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest


About Akouos

Akouos Inc. is a precision genetic medicine company. The Company is focused on developing gene therapies with the potential to restore, improve, and preserve high-acuity physiologic hearing for people worldwide who live with disabling hearing loss. The Company has developed a precision genetic medicine platform that incorporates a vector library consisting of variants of a small virus commonly used in gene therapy, known as adeno-associated virus (AAV) and a delivery approach. The Company is focused on executing on its strategic initiatives, which include the advancement of its lead product candidate, AK-OTOF, and expansion of its pipeline and development of internal manufacturing capabilities. In addition to this, the Company’s other programs include CLRN1 for Usher Type IIIA and GJB2 for a common form of monogenic deafness and hearing loss.

Stock Analysis

last close $5.76
1-mo return -31.7%
3-mo return -41.3%
avg daily vol. 116.01T
52-week high 22.88
52-week low 5.67
market cap. $284M
forward pe -
annual div. -
roe -25.7%
ltg forecast 12%
dividend yield -
annual rev. $--
inst own. 96.9%

Subscribe now for daily local and international financial news